{"schema_version":"secwatch.filing_event.v1","accession":"0001099800-23-000003","form_type":"8-K","ticker":"EW","cik":"0001099800","company_name":"Edwards Lifesciences Corp","filed_at":"2023-01-31T23:59:59+00:00","discovered_at":"2026-05-14T18:03:43.863534+00:00","generated_at":"2026-06-20T04:56:53.541993+00:00","sec_items":["2.02","9.01"],"event_type":"earnings","sentiment":"neutral","materiality_score":0.8,"calibrated_materiality_score":0.8,"confidence":"high","headline":"Edwards Q4 sales up 1% to $1.35B; adjusted EPS grows 25% to $0.64","bullets":["Q4 TAVR sales flat at $868M; constant-currency growth 5%; U.S. procedures rose mid-single digits.","Full-year 2022 sales $5.38B (+3%); adjusted EPS $2.48 (+12% YoY).","Repurchased $1.7B of stock in 2022; $900M remaining under authorization.","Q4 adjusted gross margin improved to 81.0% from 76.8% a year ago.","Reiterated 2023 outlook: sales growth 9-12% ($5.6-$6.0B); adjusted EPS $2.45-$2.60."],"urls":{"canonical":"https://secwatch.observer/filing/0001099800-23-000003","json":"https://secwatch.observer/filing/0001099800-23-000003.json","markdown":"https://secwatch.observer/filing/0001099800-23-000003.md","text":"https://secwatch.observer/filing/0001099800-23-000003.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1099800/000109980023000003/0001099800-23-000003-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1099800/000109980023000003/ew-20230131.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-06-20T04:56:53.541993+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[{"claim_id":"086a0d3c8fce847d83f20e871e7c835e32b4bce1","claim":"Edwards Lifesciences Corp reported quarter ended December 31, 2022 results: revenue $1.35 billion, EPS $0.65.","evidence_excerpt":"Edwards Lifesciences (NYSE: EW) today reported financial results for the quarter ended December 31, 2022. Highlights and Outlook • Q4 sales grew 1 percent to $1.35 billion; constant currency 1 sales grew 7 percent • Q4 TAVR sales were flat; constant currency sales grew 5 percent • Q4 EPS of $0.65; adjusted 1 EPS increased 25 percent to $0.64","evidence_source":"SEC 8-K Item 2.02","evidence_url":"https://www.sec.gov/Archives/edgar/data/1099800/000109980023000003/0001099800-23-000003-index.htm","confidence":0.95,"family_label":"Earnings Releases","details":[{"label":"Period","value":"quarter ended December 31, 2022"},{"label":"Revenue","value":"$1.35 billion"},{"label":"EPS","value":"$0.65"},{"label":"Result","value":"reported results"}],"fact_type":"earnings_release"},{"claim_id":"542af1bf3c085d129418f99864211b33a04a95d8","claim":"Edwards Lifesciences Corp reported first quarter of 2023 results: revenue $1.37 to $1.45 billion, EPS $0.58 to $0.64. Guidance initiated.","evidence_excerpt":"For the first quarter of 2023, the company projects total sales to be between $1.37 and $1.45 billion, and adjusted EPS of $0.58 to $0.64.","evidence_source":"SEC 8-K Item 2.02","evidence_url":"https://www.sec.gov/Archives/edgar/data/1099800/000109980023000003/0001099800-23-000003-index.htm","confidence":0.95,"family_label":"Earnings Releases","details":[{"label":"Period","value":"first quarter of 2023"},{"label":"Revenue","value":"$1.37 to $1.45 billion"},{"label":"EPS","value":"$0.58 to $0.64"},{"label":"Guidance","value":"initiated"},{"label":"Result","value":"guidance update"}],"fact_type":"earnings_release"},{"claim_id":"9b59911a8f550fe951e29d437a6cac0ab3678e1f","claim":"Edwards Lifesciences Corp reported full year 2023 results: revenue $5.6 to $6.0 billion, EPS $2.45 to $2.60. Guidance reaffirmed.","evidence_excerpt":"Overall, the company is reaffirming the sales guidance it provided at the December investor conference for all product groups. Full year 2023 sales are expected to grow 9 to 12 percent to $5.6 to $6.0 billion. Additionally, the company continues to expect full year 2023 adjusted earnings per share of $2.45 to $2.60.","evidence_source":"SEC 8-K Item 2.02","evidence_url":"https://www.sec.gov/Archives/edgar/data/1099800/000109980023000003/0001099800-23-000003-index.htm","confidence":0.95,"family_label":"Earnings Releases","details":[{"label":"Period","value":"full year 2023"},{"label":"Revenue","value":"$5.6 to $6.0 billion"},{"label":"EPS","value":"$2.45 to $2.60"},{"label":"Guidance","value":"reaffirmed"},{"label":"Result","value":"guidance update"}],"fact_type":"earnings_release"},{"claim_id":"c222a8391d2074e9035f15a30da97f59ba4e0fb3","claim":"Edwards Lifesciences Corp reported year ended December 31, 2022 results: revenue $5.38 billion, EPS $2.44.","evidence_excerpt":"Sales for the year ended December 31, 2022, were $5.38 billion, a year-over-year increase of 3 percent, or 8 percent on an underlying basis. Although initial sales expectations for 2022 anticipated a better healthcare environment, the company delivered balanced contributions across each of its product groups and regions. Diluted earnings per share for 2022 were $2.44, while adjusted earnings per share of $2.48 increased 12 percent from the year-ago period.","evidence_source":"SEC 8-K Item 2.02","evidence_url":"https://www.sec.gov/Archives/edgar/data/1099800/000109980023000003/0001099800-23-000003-index.htm","confidence":0.95,"family_label":"Earnings Releases","details":[{"label":"Period","value":"year ended December 31, 2022"},{"label":"Revenue","value":"$5.38 billion"},{"label":"EPS","value":"$2.44"},{"label":"Result","value":"reported results"}],"fact_type":"earnings_release"}],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}